Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
Because of the demonstrated single agent activity and excellent tolerability in patients with
refractory non-small cell lung cancer, ZD1839 may be of benefit in the first-line treatment
of patients with advanced non-small cell lung cancer who have poor performance status. In
this phase II trial, we will investigate the single agent activity of first-line ZD1839 in
patients with advanced non-small cell lung cancer with poor performance status